Camel!!! Where you been boy?! Welcome back. Stoney's been knocking them out of the park here. (Other than his market timing when it comes to the indexes.That never changes. Horrible) But his stock picks are top notch! Stocks like MP....
Wedbush gets more bullish on AMC Entertainment, upgrades shares » 06:54 AMC DAY 6 GM~~ I am so frustrated. I had an amazing parlay going that would of returned $400 one leg had already hit Elle stolen base Reds game and all the Yankee Mariner game had to do was stay under 9.5 runs. It was 2-0 Mariners and their pitcher had a no hitter going my cash out was $300 plus. I counted it in the win column. Ignored the cash out offer. Then the Mariners changed pitchers, then Stanton hit a pinch hit HR that made the score within 3 then in the 9th inning the Yankees scored three times to tie and then won. The game went over.
Janux Therapeutics initiated with bullish view at Raymond James, » 06:46 JANX Citi ups Arista Networks target, opens 'positive catalyst watch' » 06:36 ANET Truist upgrades Astronics to Buy on ramping MAX production » 06:29 ATRO Goldman testing first Transgender autonomous coder called Devin, CNBC reports » 05:37 GS RARE Ultragenyx Pharmaceutical Inc. $31.04-10.40(-25.11%)4:00 PM 07/10/25 NASDAQ |$USD |Pre-Market:$31.31+0.27(+0.89%)7:00 AM $29 was your best spot yesterday $30 the obvious buy point. I don't know as of this moment whether the HF followed through yesterday// I'll know at the open today. If not there is still lots of time to enter this name.// Complicated situation I'll try and sum up with coffee here-- they did not get rejected. They had a phase 2/3 going and in those often you hope to end the trials early. They were advised to finish off a new phase 3- they have an complimentary trial going that enters phase 3 anyway so now they will report both trials together. Is it a set back? Yes. Is the timeline more drawn out now. Yes. Will the trial ultimately succeed-- 85% yes. With some year 25' tail end action - this idea can be a foundation piece for a sloppy market. Already de risked to a certain extent it will most likely be dead money until sudden upside. To me the upside event is still in place.
$31. This name is very interesting. They have over 2,000 employees they service defense & space. The PE is only 20 despite stomping the market returns. This is like Howmet Aerospace in feel. 11% short<---- EPS + 40% PE 20 Return on. equity could be alot better 6 months UP 93%<------ vs S&P up 7%. $24 mil cash vs $196 mil debt They have been around since 1968. Usually an $8 stk.
Company Profile Astronics Corporation, through its subsidiaries, designs and manufactures products for the aerospace, defense, and electronics industries in the United States, rest of North America, Asia, Europe, South America, and internationally. It operates in two segments, Aerospace and Test Systems. The Aerospace segment offers lighting and safety systems, electrical power generation systems, distribution and seat motions systems, aircraft structures, avionics products, systems certification, and other products. This segment serves airframe manufacturers (OEM) that build aircraft for the commercial transport, military, and general aviation markets; suppliers to OEMs; and aircraft operators, such as airlines; suppliers to the aircraft operators; and branches of the U.S. Department of Defense. The Test Systems segment designs, develops, manufactures, and maintains automated test systems that support the aerospace and defense, communications, and mass transit industries, as well as training and simulation devices for commercial and military applications. This segment serves OEMs and prime government contractors for electronics and military products. Astronics Corporation was incorporated in 1968 and is headquartered in East Aurora, New York.
The Art Of The Sell might be a book I write or a lecture I give to new investors. We exited this name at $66 and it's $25 now/ I need to due some DD here to figure out what happened I know I followed a huge insider sell which you never want to see with an emerging Bio.. but what now? I'll check for new insider action.
I have to go through my whole history but i know I sold this name at the HF. I had a gain but nothing special. I had been on this idea last year/// THIS BIO HAS REVENUE!!! THAT CAN BE A CURSE. BUT IF IT FLOWS THROUGH TO PROMISING CANDIDATES IN THE PIPELINE CAN HELP AVOID DILUTION<------ The most recent consensus for Zymeworks from its seven analysts is for revenues of US$123m in 2025 which, if met, would be a huge the most recent consensus for Zymeworks from its seven analysts is for revenues of US$123m in 2025 which, if met, would be a huge 32% increase on its sales over the past 12 months. The loss per share is anticipated to greatly reduce in the near future, narrowing 23% to US$1.26. Yet before this consensus update, the analysts had been forecasting revenues of US$94m and losses of US$1.65 per share in 2025. on its sales over the past 12 months. Stifel analysts reiterated their Buy rating for Zymeworks stock (NASDAQ: ZYME) with a price target of $28.00, representing significant upside potential from the current price of $11.64
The analysts expressed confidence in the ability of zanidatamab combined with chemotherapy to outperform the standard-of-care trastuzumab combined with chemotherapy. The ongoing Phase 3 HERIZON-GEA-01 trial, which is expected to release topline data in the second half of 2025, is anticipated to further validate these findings.InvestingPro analysis shows Zymeworks maintains a healthy financial position with a current ratio of 4.71 and more cash than debt on its balance sheet, providing adequate runway for its clinical programs. The approximately three-year median overall survival observed in the study was highlighted as particularly notable. Tuesday, Zymeworks shares, currently trading at $11.82, received a positive outlook from TD Cowen as the firm initiated coverage with a Buy rating. The research firm highlighted the company’s unique platform of Antibody-Drug Conjugates (ADCs) and multispecific T-cell engagers (TCEs) within the oncology and auto-immune and inflammatory diseases (AIID) sectors. TD Cowen’s analysis points to Zymeworks’ product, Ziihera, which is licensed to JAZZ Pharmaceuticals and ONCOLOGY VENTURE, as having the potential to be a blockbuster following its approval in second-line Biliary Tract Cancer (2L BTC). The company, currently valued at $824 million, has demonstrated impressive revenue growth of 85% over the last twelve months. The firm anticipates that upcoming data in first-line Gastroesophageal Adenocarcinoma (1L GEA), expected to be positive, will serve as a significant catalyst for the company in the second half of 2025. The analyst from TD Cowen believes that the royalties from Ziihera will provide sufficient funding for Zymeworks’ innovative pipeline, which includes projects that are either in or entering Phase 1 clinical trials within the next one to two years. keep a close eye on Zymeworks as it progresses through various stages of clinical development, with the second half of 2025 marked as a particularly significant period for the company’s trajectory.
Gauzy jumps 30% as CEO and long-term investor buy stock Jul. 11, 2025 7:47 AM Gauzy Ltd. (GAUZ) Gauzy (NASDAQ:GAUZ) stock price climbed over 30% on Friday during pre-market trade as it said that CEO and Co-Founder Eyal Peso, and its second largest, long-time investor and director nominee, Alejandro Weinstein,bought560,000 of Gauzy ordinaryshares from an existing shareholder. The private transaction was negotiated and signed in H1 June 2025. Mr. Peso’s investment was financed entirely through a personal loan. "This investment reflects our steadfast belief in Gauzy's exceptional growth potential," commented Mr. Peso. "Having witnessed Gauzy's evolution firsthand, I am more confident than ever in the Company's short-term roadmap for profitability, breakthrough technologies, and vision for the future." said Weinstein.
ZYME Zymeworks Inc.- 1 MONTH UP 8% $13.66 0.09(+0.66%)4:00 PM 07/10/25 NASDAQ |$USD |Market Close STRONG RESISTANCE @$15 <------ LT POTENTIAL = $27-$32